Drugs & Targets Vyxeos gets FDA approval for first treatment for types of poor-prognosis AML August 04, 2017Vol.43 No.31
Drugs & Targets Opdivo gets FDA accelerated approval for MSI-H/dMMR colorectal cancer August 04, 2017Vol.43 No.31
Drugs & Targets Amgen, Allergan submit biosimilar application for ABP 980 to FDA August 04, 2017Vol.43 No.31
Drugs & Targets Kite files the first CAR-T application in Europe for axicabtagene ciloleucel August 04, 2017Vol.43 No.31
Drugs & Targets BMS to acquire IFM Therapeutics to focus on innate immunity August 04, 2017Vol.43 No.31
Drugs & Targets BMS, Clovis form collaboration to evaluate Opdivo and Rubraca August 04, 2017Vol.43 No.31
Drugs & Targets Loxo Oncology acquires highly selective, reversible BTK inhibitor August 04, 2017Vol.43 No.31
Drugs & Targets MedStar Health partners with Indivumed to advance precision oncology research August 04, 2017Vol.43 No.31
In Brief Ramon Parsons named director of Tisch Cancer Institute at Mt. Sinai August 04, 2017Vol.43 No.31
